lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12...345678910111213...4546»
  • ||||||||||  Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
    Trial primary completion date:  DPART: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (clinicaltrials.gov) -  Mar 23, 2022   
    P4,  N=190, Recruiting, 
    Trial primary completion date: Dec 2021 --> Apr 2022
  • ||||||||||  Review, Journal:  Pharmacological treatment of COVID-19: an opinion paper. (Pubmed Central) -  Mar 18, 2022   
    The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients. (Pubmed Central) -  Mar 16, 2022   
    sgRNA showed similar variation in the standard care and Lopinavir-Ritonavir group...E sgRNA levels in the initial infection showed no correlation with the serum antibody against spike, nucleoprotein, and receptor binding domains at ten days later. sgRNA lasted a long period in COVID-19 patients and might have little effect on humoral response.
  • ||||||||||  Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Clinical, Retrospective data, Journal:  Network meta-analysis of post-exposure prophylaxis randomized clinical trials. (Pubmed Central) -  Mar 15, 2022   
    sgRNA lasted a long period in COVID-19 patients and might have little effect on humoral response. Our study shows the advantages of integrase inhibitors when used as PEP, particularly EVG as a Single-Tablet Regimen.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
    Review, Journal:  TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE. (Pubmed Central) -  Mar 15, 2022   
    Concerning plasmapheresis and intravenous immunoglobulins, both can be used in COVID-19 while taking into consideration thromboembolic properties of the former and hemodynamic disturbances of the latter. As current data suggest, all known COVID-19 vaccines are safe to use in MG patients.
  • ||||||||||  Nexplanon (etonogestrel implant) / Organon
    Enrollment open:  Kuwa Free! - Live Free! (clinicaltrials.gov) -  Mar 9, 2022   
    P=N/A,  N=700, Recruiting, 
    In a small randomized study of adults starting ART with Pf SCP, no statistically significant differences were seen between LPV/r- and nNRTI-based ART in Pf SCP clearance after 15 days of treatment. Not yet recruiting --> Recruiting
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard
    Retrospective data, Journal:  Meta-analysis of arbidol versuslopinavir/ritonavir in the treatment of coronavirus disease 2019. (Pubmed Central) -  Mar 5, 2022   
    Arbidol may be superior tolopinavir/ritonavir in the treatment of COVID-19. However, due to the small number of included studies and the number of patients, high-quality multi-centre large-sample randomized double-blind controlled trials are still needed for verification.
  • ||||||||||  Calquence (acalabrutinib) / AstraZeneca
    Trial completion, Trial completion date:  Public Health Emergency: SOLIDARITY TRIAL Philippines (clinicaltrials.gov) -  Mar 2, 2022   
    P=N/A,  N=1314, Completed, 
    Communicated by Ramaswamy H. Sarma. Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Apr 2021
  • ||||||||||  hydroxychloroquine / Generic mfg., dexamethasone / Generic mfg.
    Observational data, Journal:  COVID-19 treatments sold online without prescription requirements in the United States. (Pubmed Central) -  Feb 25, 2022   
    We document that illegitimate online pharmacies sidestep prescription requirements, skirt pharmacist counselling, and make false claims regarding efficacy in treating COVID-19 infections. Health care professionals must urgently educate the public of the dangers of purchasing drugs from illegitimate websites and highlight the importance of seeking treatment through authentic avenues of care.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  Current status of therapeutic alternatives for COVID-19: A narrative review. (Pubmed Central) -  Feb 12, 2022   
    The discussion includes antiviral agents (hydroxychloroquine, lopinavir/ritonavir, remdesivir, favipiravir and ivermectin) and, various immunomodulatory drugs (corticosteroids, tocilizumab, baricitinib, and IL-1 inhibitors). Other investigational therapies including darunavir/cobicistat, umifenovir, sofosbuvir/daclatasvir, sofobuvir/ledipasvir, ribavirin, nitazoxanide and interferon-based regimens were not evaluated due to insufficient data on the efficacy and safety of these agents.
  • ||||||||||  hydroxychloroquine / Generic mfg.
    Review, Journal:  A dossier on COVID-19 chronicle. (Pubmed Central) -  Feb 10, 2022   
    Several subunit vaccines, peptides, nucleic acids, plant-derived, and recombinant vaccines are under pipeline. Research work, development of new medicines and vaccines, and efforts to reduce disease morbidity and mortality must be encouraged to improve our position in the fight against this disease and to protect human life.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Journal:  Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. (Pubmed Central) -  Feb 8, 2022   
    We recommend against using hydroxychloroquine ± azithromycin or lopinavir-ritonavir...We recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation...We also recommend using low-dose corticosteroids in patients with refractory shock requiring vasopressor support. We recommend against the use of convalescent plasma and interleukin-6 inhibitors, such as tocilizumab, for the treatment of COVID-19 in LMICs outside of clinical trials.
  • ||||||||||  trimethoprim/sulfamethoxazole / Generic mfg., nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
    IS ROUTINE PCP PROPHYLAXIS NEEDED IN VERY EARLY-TREATED INFANTS WITH HIV? ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_1203;    
    Lopinavir/ritonavir was added when age-appropriate; NVP was discontinued 12 weeks after confirmed virologic suppression...The majority of infants treated shortly after birth with suppressive ART maintain high CD4 cell counts and percentages through their 1st year of life. Routine PCP prophylaxis guidelines for infants with consistently high CD4 cell counts/percentages in settings where malaria or severe bacterial infections are not highly prevalent may warrant re-evaluation.
  • ||||||||||  rifampicin / Generic mfg.
    SUBOPTIMAL LOPINAVIR EXPOSURE ON 8-HOURLY LPV/r 4:1 IN HIV/TB-COINFECTED CHILDREN ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_703;    
    LPV/r oral solution given in increased doses 8-hourly alongside rifampicin did not reach adequate LPV concentrations, and therefore unsuitable for HIV/TB co-infected children. The subtherapeutic exposures observed after TB treatment raise questions about the bioavailability of LPV/r oral solution in this population and supports the rapid transition to dolutegravir-based ART.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods, dolutegravir/emtricitabine/tenofovir alafenamide (DTG/FTC/TAF) / Mylan
    PREDICTORS OF VIRAL SUPPRESSION FOLLOWING ENHANCED ADHERENCE COUNSELING: VISEND TRIAL ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_638;    
    1000 copies/mL) ART of tenofovir disoproxil fumarate (TDF), lamivudine (3TC) plus efavirenz (EFV) or nevirapine (NVP), switched to 1) TDF,3TC,DTG or 2) tenofovir alafenamide (TAF), emtricitabine (FTC),DTG or 3) lopinavir/ritonavir (LPV/r) or atazanavir/r (ATV/r), zidovudine (ZDV),3TC...The overall VS rates following EAC among individuals with virologic failure was 66%; broken down as follows: TAF,FTC,DTG (78%), TDF,3TC,DTG (71%), ZDV,3TC,ATV/r (62%), and ZDV,3TC,LPV/r (53%)...In the VISEND trial, EAC led to VS rates near the WHO target of 70% with disparities in outcomes according to gender, education, and other factors. There is a need to routinely incorporate EAC into clinical trials and practice before regimen switch in order to maximize outcomes.
  • ||||||||||  Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
    PHARMACOGENETICS OF BEDAQUILINE AND CLOFAZIMINE PLASMA CLEARANCE AMONG SOUTH AFRICANS ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_544;    
    Different CYP3A5*3 minor allele frequencies among populations (30% in Africans, 70% in East Asians, 93% in Europeans) may explain the more rapid BDQ clearance previously reported in people of African ancestry. The genome-wide significant association of CNTN5 rs75285763 with CFZ clearance is likely a chance finding.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    DOLUTEGRAVIR WITH RECYCLED nRTIs IS NONINFERIOR TO PI-BASED ART: VISEND TRIAL ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_390;    
    We conducted a 144 week, randomized, open-label, phase 3 noninferiority trial in Zambia where we randomized adults on tenofovir disoproxil fumarate (TDF), lamivudine (3TC) plus efavirenz (EFV) or nevirapine (NVP)...In Arm B, those with VL ?1000 copies/mL were randomized to TLD, TAFED, or the standard-of-care (SOC) second line protease inhibitor (PI/r)-based regimen lopinavir/ritonavir (LPV/r) or atazanavir/r (ATV/r), zidovudine (ZDV), 3TC...In the VISEND trial, HIV-positive adults with virologic failure to TDF/3TC/NNRTI, had favorable outcomes when switched to DTG with either TAF/FTC or TDF/3TC compared to those switched to SOC boosted-PI ART. Women receiving DTG, however, due to significant weight gain, may be at heightened risk for non-communicable diseases and/or metabolic complications hence longer-term follow up is needed.
  • ||||||||||  10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
    TREATMENT WITH BROADLY NEUTRALIZING ANTIBODIES IN CHILDREN WITH HIV IN BOTSWANA ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_268;    
    In this proof-of-concept study, dual bNAb treatment with VRC01LS and 10-1074 maintained viral suppression for 24 weeks in the absence of ART in 44% of children, and was well-tolerated. Newer bNAb combinations with greater breadth and potency, used in children with favorable pre-treatment characteristics and possibly with longer bNAb/ART overlap, may improve treatment success for this novel ART-sparing strategy.
  • ||||||||||  nevirapine / Generic mfg., lopinavir/ritonavir / Generic mfg.
    TWO-YEAR VIROLOGIC OUTCOMES OF VERY EARLY ART FOR INFANTS IN THE IMPAACT P1115 STUDY ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_267;    
    440 high-risk infants (Cohort 1) were enrolled and initiated presumptive nevirapine (NVP)-based ART by age 48 hours; 34 with in utero infection continued ART...Lopinavir/ritonavir was added when age appropriate; NVP was stopped 12 weeks after confirmed HIV-1 plasma viral load (VL) <20 (Roche TQ) or <40 c/mL (Abbot RT)...The estimated probability of remaining potentially eligible for ART interruption at age 2 years was 33% (21%-46%). Infants with in utero HIV-1 infection who maintain virologic suppression with very early ART can achieve restricted HIV-1 reservoirs by age 2 years, which may enable ART-free remission.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Review, Journal:  An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. (Pubmed Central) -  Feb 3, 2022   
    Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved...We focus on currently recommended therapeutic agents, including steroids, various monoclonal antibodies, remdesivir, baricitinib, anticoagulants and PAXLOVID™ summarizing the latest original studies and meta-analyses...The results of recent studies report that hydroxychloroquine and convalescent plasma demonstrate no efficacy against SARS-CoV-2 infection. Lastly, we summarize the studies on various drugs with incoherent or insufficient data concerning their effectiveness, such as amantadine, ivermectin, or niclosamide.